Media coverage about Cellectis (NASDAQ:CLLS) has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7143726733842 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities research analysts recently weighed in on CLLS shares. Wells Fargo & Company restated an “outperform” rating and issued a $40.00 target price (up previously from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. SunTrust Banks lowered shares of Cellectis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $35.00 to $20.00 in a report on Tuesday, September 5th. Jefferies Group restated a “buy” rating and issued a $47.00 target price on shares of Cellectis in a report on Sunday, October 29th. Zacks Investment Research upgraded shares of Cellectis from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a report on Tuesday, October 24th. Finally, Nomura lowered their target price on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $39.29.
Shares of Cellectis (NASDAQ:CLLS) opened at $27.42 on Monday. Cellectis has a fifty-two week low of $16.32 and a fifty-two week high of $35.07.
ILLEGAL ACTIVITY NOTICE: “Cellectis (CLLS) Given Media Impact Score of 0.28” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/18/cellectis-clls-given-media-impact-score-of-0-28.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.